Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan

Vaccine

Volumn 28, Issue 43, 2010, Pages 7063-7069

  Kawakami, Kenji ^a   Ohkusa, Yasushi ^b   Kuroki, Reiki ^a   Tanaka, Takeshi ^a   Koyama, Kazuhiko ^a   Harada, Yoshitaka ^a   Iwanaga, Kouichi ^c   Yamaryo, Takeshi ^a   Oishi, Kazunori ^d  

^a Nagasaki Kawatana Medical Center   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Medical Association of Higashisonogi District   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Cost analysis; Influenza vaccine; Pneumococcal polysaccharide vaccine; Pneumonia

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VACCINATION; WALKING DIFFICULTY;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFLUENZA VACCINES; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL;

EID: 77957364220     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.010     Document Type: Article

References (36)

1. O'Brien K.L., Wolfsan L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Baggett H.C., Peruski L.F., Olsen S.J., Thamthitiwat S., Rhodes J., Dejsirilert S., et al. Incidence of pneumococcal bacteremia requiring hospitalization in rural Thailand. Clin Infect Dis 2009, 48:S65-S74.
3. Brown P.D., Lerner S.A. Community-acquired pneumonia. Lancet 1998, 352:1295-1302.
4. Oishi K., Yoshimine H., Watanabe H., Watanabe K., Tanimura S., Kawakami K., et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology 2006, 11:429-436.
5. Jackson L.M., Neuzil K.M., Thompson W.W., Shay D.K., Yu O., Hanson C.A., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004, 39:1642-1650.
6. Nelson J.C., Jackson M., Yu O., Whitney C.G., Bounds L., Bittner R., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community-acquired pneumonia in children and adults. Vaccine 2008, 26:4947-4954.
7. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1328-1338.
8. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Eng J Med 1991, 325:1453-1460.
9. 23-valent pneumococcal polysaccharide vaccine. WHO Position Wkly Epidemiol Rec 2008, 83:373-384.
10. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet 2000, 355:2106-2111.
11. Fisman D.N., Abrutyn E., Spaude K.A., Kim A., Kirchner C., Daley J. Prior pneumococcal vaccination is associated with reduced death, complication, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006, 42:1093-1101.
12. Johnstone J., Marrie T.J., Eurich D.T., Majumdar S.R. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007, 167:1938-1943.
13. Jackson L.A., Neuzil K.M., Yu O.M., Benson P., Barlow W., Adams A.L., et al. Effectiveness of pneumococcal vaccine in older adults. N Eng J Med 2003, 348:1747-1755.
14. Ortqvist A., Hedlund J., Burman L., Elbel E., Hofer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998, 399-403.
15. Garber A.M., Phelps C.E. Economic foundations of cost-effectiveness analysis. J Health Eco 1997, 16:1-31.
16. Evers S.M., Ament A., Colombo G.L., Konradsen H.B., Reinert R.R., Sauerland D., et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007, 26:531-540.
17. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004, 19:365-375.
18. Ogilvie I., Khoury A.E., Cui Y., Dasbach E., Grabenstein J.D., Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccine in adults: a systemic review of conclusions and assumptions. Vaccine 2009, 27:4891-4904.
19. Ament A., Baltussen R., Duru G., Rigaud-Bully C., de Graeve D., Ortqvist A., et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries. Clin Infect Dis 2000, 31:444-450.
20. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Eng J Med 2006, 354:1667-1669.
21. Wang R., Lagakos S.W., Ware J.H., Hunter D.J., Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Eng J Med 2007, 357:2189-2194.
22. Manning W.G., Morris C.N., Newhouse J.P. A two-part model of the demand for medical care: preliminary results from the health insurance study. Health, economics, and health economics 1981, 103-123. North-Holland Pub Co, Amsterdam. J. van der Gaag, M. Perlman (Eds.).
23. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983, 78:605-610.
24. Duan N., Manning W.G., Morris C.N., Newhouse J.P. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983, 1:115-126.
25. Duan N., Manning W.G., Morris C.N., Newhouse J.P. Choosing between the sample-selection model and the multipart model. J Bus Econ Stat 1984, 2:283-289.
26. Gutierrez F., Masia M., Mirete C., Soldán B., Rodríguez J.C., Padilla S., et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia cause by different microbial pathogens. J Infect 2006, 53:166-174.
27. Lipsky B.A., Boyko E.J., Inui T.S., Koepsell T.D. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986, 146:2179-2185.
28. Marrie T.J. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000, 31:1066-1078.
29. Loeb M., McGeer A., McArthur M., Walter S., Simor A.E. Risk factors for pneumonia and other lower respiratory infections in elderly residents of long-term care facilities. Arch Intern Med 1999, 159:2058-2064.
30. Kikuchi R., Watabe N., Konno T., Mishina N., Sekizawa K., Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994, 150:251-253.
31. Nakagawa T., Sekizawa K., Arai H., Kikuchi R., Manabe K., Sasaki H. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997, 157:321-324.
32. Chen M., Hisatomi Y., Furumoto A., Masaki H., Nagatake T., Sueyasu Y., et al. Comparative immune response of patients with chronic pulmonary diseases during the 2 year period after pneumococcal vaccination. Clin Vaccine Immunol 2007, 14:139-145.
33. Furumoto A., Ohkusa Y., Chen M., Kawakami K., Masaki H., Sueyasu Y., et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008, 26:4284-4289.
34. Christenson B., Hedlund J., Lundbergh P., Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004, 23:363-368.
35. Chiba H., Ohrui T., Matsui T., Fukushima T., Sasaki H. Benefits of pneumococcal vaccination for bedridden patients. J Am Geriatr Soc 2004, 52:1410.
36. Maruyama T., Taguchi O., Niederman M.S., Moser J., Kobayashi H., Kobayashi T., et al. Efficacy of 23-valet pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomized and placebo controlled trial. BMJ 2010, 340:c1004.